SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as retail investors and community members speculate on a potential short squeeze, citing record-high short interest and heavy insider ownership within the current political administration. The conversation is further fueled by the upcoming acquisition of Northern Data and strategic partnerships with Tether, which investors believe will significantly boost cloud capacity and revenue growth.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing a massive, sentiment-driven rally fueled by intense short squeeze dynamics, prompting the community to debate the sustainability of these record-breaking price levels. Investors are actively discussing the influence of institutional positioning and liquidity constraints, while many express caution over the stark disconnect between the stock's parabolic technical move and its underlying debt-heavy fundamentals.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending sharply as investors react to a significant collaboration with NVIDIA, which integrates its safety-critical QNX OS into advanced edge AI systems for automotive, medical, and robotics applications. The community is actively debating this potential shift from a legacy software firm to a key player in physical AI, driving high-volume momentum and renewed interest in the stock's long-term valuation.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is surging as investors react to a new executive order prioritizing the development and review of psychedelic medicines, including ibogaine. The community is heavily focused on the stock's low float and high potential for a short squeeze, while also debating the firm's long-term regulatory prospects versus its current volatility.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is trending as retail investors rally behind new strategic investments in Astrikos.AI and ongoing partnerships with Yotta, viewing the company as an undervalued AI infrastructure play. The community is actively debating the stock's future amid tight warrant liquidity and speculation that long-term project pipelines will finally drive a significant breakout.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending amid significant downward pressure, with investors heavily debating the impact of ongoing share dilution, institutional selling, and the appointment of a new CEO from the elevator industry. While some traders are attempting to catch a falling knife by betting on a potential rebound tied to the company's Saudi backing and long-term robotaxi partnerships, the broader community remains deeply skeptical due to sustained losses, continuous cash burn, and the stock hitting new all-time lows.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently trending due to the company reaching a critical milestone with successful Phase 3 trial results for its psilocybin-based treatment, COMP360, for treatment-resistant depression. The community is actively discussing the stock's potential for FDA approval and future commercialization, while debating the impact of a recent public offering on short-term price volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing heightened volatility following its latest earnings report, where a solid revenue beat was overshadowed by conservative Q2 guidance and the unexpected news of a co-founder's departure from the board. The community remains deeply divided, with many traders debating whether this dip represents a prime buying opportunity for a long-term compounder or a signal of further downside risk as bearish sentiment and institutional shorting patterns intensify.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is trending due to anticipation of a significant revenue ramp for its CAR-T therapy, Carvykti, following label expansion and ongoing manufacturing capacity upgrades. The community is actively discussing strong institutional interest, potential M&A buyout rumors with partners like Johnson & Johnson, and the stock's long-term valuation upside as it moves toward profitability.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing a significant surge in momentum as the stock breaks past a long-term downtrend, fueled by continued aggressive Bitcoin accumulation and the announcement of a new semi-monthly dividend structure for its preferred shares. Market participants are actively debating the sustainability of this rally, with bulls highlighting the stock's role as a levered proxy for Bitcoin's upward movement, while shorts remain under intense pressure amid a sharp increase in trading volume.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares.</li><li>Atai is now preparing for its investigational psychedelic drug BPL-003 to enter a late-stage trial this quarter.</li><li>Further, data from Atai’s mid-stage trial of VLS-01 in treatment-resistant depression is expected in the second half of 2026.</li></ul> Shares of AtaiBeckley Inc. (ATAI) surged 28% on Monday and are on track for their best single-day gain if the rally holds, following analyst price target hikes and growing optimism across the psychedelic drug sector after President Trump signed an executive order to accelerate research in the field.Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, while also committing $50 million to federal research into the psychedelic compound called ibogaine.The move boosted shares of companies including Definium Therapeutics (DFTX), Compass Pathways (CMPS), Enveric BioSciences (ENVB), and Psyence Biomedical (PBM), among others.<h2 class="st-heading-2">Wall Street Boost</h2>Separately, Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares. Atai is now preparing for BPL-003 to enter a late-stage trial this quarter. The investigational drug is a fast-acting psychedelic designed for treatment-resistant depression (TRD) and alcohol use disorder.The analyst now expects the company to price BPL-003 at a net annual price of $30,000 at launch, in line with Janssen Pharmaceuticals's Spravato nasal spray already approved for treatment-resistant depression. Further, data from Atai’s mid-stage trial of VLS-01 in TRD is expected in the second half of 2026, the analyst noted.Guggenheim, meanwhile, raised the firm's price target on AtaiBeckley to $16 from $11 and kept a ‘Buy’ rating on the shares on Friday. The firm said that it recently met with Atai management, which reinforced its "conviction" in the BPL-003 program heading into late-stage initiation this quarter, the analyst told investors.According to data from Koyfin, all 14 analysts covering ATAI rate it ‘Buy’ or higher. The 12-month average price target on the stock is $13.83, representing a potential upside of about 166% from current trading levels.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ATAI stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed optimism about the stocks of psychedelic drug developers including ATAI to “trend up for a while.” “This will be a good ride,” they said.<stembedurl>https://www.stocktwits.com/twiggs462/message/650773904</stembedurl>Another user cheered Atai’s great assets and voiced hopes for further rallies in future.<stembedurl>https://www.stocktwits.com/brunoq14/message/650772195</stembedurl><a href="https://stocktwits.com/symbol/ATAI">ATAI stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/agio-stock-slumps-whats-the-novo-connection/cZBd0tMRIzi">AGIO Stock Slumps 25% – What’s The Novo Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ATAI Stock Soars On Track For Best Day On Trump Psychedelics Push And Wall Street Cheers

Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, spurring a rally among psychedelic drug developer stocks. 

Equity

<ul class="summary-bullets"><li>The order calls on the FDA to give priority to select psychedelic treatments that have demonstrated positive results in preliminary research.&nbsp;</li><li>The treatments could qualify for priority review, enabling regulators to assess them faster while upholding safety requirements.</li><li>COMP360, Compass’s psilocybin therapy in late-stage trials, has shown relief within a day, with effects lasting up to six months after one or two doses.&nbsp;</li></ul>Compass Pathways (CMPS) stock gained overnight on Sunday as the company voiced support for the White House’s executive action to speed up research, approval, and availability of psychedelic-based treatments.The company specializes in psilocybin therapies, which stand to benefit from faster regulatory timelines tied to its lead candidate.&nbsp;<h2 class="st-heading-2">Regulatory Changes To Speed Access</h2>President Donald Trump on Saturday signed the order to speed up the development, review, and accessibility of treatments targeting complex psychiatric conditions. The policy outlines a coordinated effort across federal agencies to reduce regulatory delays and expand research opportunities. The order instructs the Food and Drug Administration (FDA) to prioritize certain psychedelic drugs that have already shown promise in early studies.&nbsp;These therapies may receive special review vouchers, allowing regulators to evaluate them more quickly without compromising safety standards. In parallel, the FDA and the Drug Enforcement Administration are tasked with designing pathways that permit eligible patients to access investigational treatments still under review, provided they meet baseline safety criteria.<h2 class="st-heading-2">Compass Lead Candidate Gains Momentum</h2>Compass said it is already engaged in ongoing review discussions with the FDA, positioning it to capitalize on the policy shift as it advances treatment for depression.<blockquote>“Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin,” said CEO Kabir Nath.</blockquote>At the center of this development is COMP360, the company’s synthetic psilocybin therapy currently in late-stage trials. Phase 3 trial findings suggest the treatment may produce rapid improvements, with patients experiencing relief within a day and sustained benefits lasting about six months after just 1 or 2 doses.<a href="https://stocktwits.com/symbol/CMPS">Compass Pathways’ stock</a> was up over 2%&nbsp;as of its last after-hours close. Peers&nbsp;Enveric Biosciences and ATAI Life Sciences were up over 3.5% and 1.1%, respectively.&nbsp;The company’s study includes data from more than 1,000 participants, indicating a generally manageable safety profile with short-lived side effects. Beyond depression, Compass is expanding its focus to PTSD, including collaboration with Veterans Affairs programs to explore treatment options.<h2 class="st-heading-2">What Are Retail Traders Saying?&nbsp;</h2>On Stocktwits, retail sentiment for Compass Pathways remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels,&nbsp;which have surged by 2,000% over the past seven days.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_19_214919_png_16ee490f83.webp" alt="CMPS’s Sentiment Meter and Message Volume as of 21:45 p.m. ET on Apr.19, 2026 | Source: Stocktwits" width="930" height="97"><figcaption>CMPS’s Sentiment Meter and Message Volume as of 21:45 p.m. ET on Apr.19, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user&nbsp;<a href="https://stocktwits.com/Canvasback33/message/650726549">expressed</a> optimism about COMP360 receiving approval and availability.&nbsp;“EO [executive order] was the last hurdle in my mind for this stock. Federal govt has cleared the run way for psychedelic medicine and the FDA is on board. I truly believe this will be approved and is going to market. This is the future of mental health.”<stembedurl>https://stocktwits.com/Canvasback33/message/650726549</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Millionaire11/message/650726940">said</a>:&nbsp;“This is not a sell the news event. This news was not expected. This will skyrocket upon FDA approval anticipation. Once FDA approved, I could see a sell the news event but for now enjoy the gains this week.”<stembedurl>https://stocktwits.com/Millionaire11/message/650726940</stembedurl>CMPS stock has declined over 3% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-china-surge-shows-pricing-power-matters-in-a-supply-crunch-retail-bulls-take-notice/cZJUsxBRIUG">Apple’s China Surge Shows Pricing Power Matters In A Supply Crunch – Retail Bulls Take Notice</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

CMPS Stock Surges As White House Psychedelic Push Prompts FDA Review, Boosts COMP360 Prospects

CMPS Stock - On Saturday, President Trump approved a measure to accelerate the development, evaluation, and availability of therapies for mental health disorders. 

CMPS Stock Jumps Overnight After Trump Order Fast-Tracks Psychedelic Therapies

On Saturday, President Trump approved a measure to accelerate the development, evaluation, and availability of therapies for mental health disorders. 


<ul class="summary-bullets"><li>The report, citing sources, said that the federal government is going to look closely at ibogaine’s safety and effectiveness.&nbsp;</li><li>According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.</li><li>The Trump administration does not intend to reclassify the drug for medical use, instead keeping it a Schedule I drug in the leagues of heroin, the report added.</li></ul>Shares of Psyence Biomedical (PBM) more than doubled on Thursday following media reports that the White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into the psychedelic compound called ibogaine.Shares of the company, which is advancing nature-derived psilocybin and ibogaine therapies, traded 141% higher at the time of writing, on track for its best session to date if gains hold.In November, the company said that it has established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs, based in Africa, as it prepares for the clinical development of ibogaine for substance use disorders.<h2 class="st-heading-2">Trump’s Upcoming Executive Order</h2>CBS News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/">reported</a>, citing sources, that the federal government is going to look closely at ibogaine’s safety and effectiveness. However, the Trump administration does not intend to reclassify the drug for medical use, instead keeping it a &nbsp;Schedule I drug in the leagues of heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote that have no acceptable medical use and high potential for abuse.According to the report, President Trump is expected to sign the executive order as soon as this week.Ibogaine is a psychoactive indole alkaloid derived from the West African Tabernanthe iboga shrub. Research into its therapeutic applications for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression is ongoing,According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans, though it is unclear how the government will help facilitate further research.An official told CBS News that medical research into ibogaine is in an early phase, but the administration wants to help determine whether it's "snake oil" or a legitimate treatment.Other companies in the field of psychedelics, including Clearmind Medicine (CMND), AtaiBeckley (ATAI), GH Research (GHRS), and Compass Pathways (CMPS) are also trading higher on the news.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PBM stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.A Stocktwits user noted that PBM stock is subject to “wild swings.”<stembedurl>https://www.stocktwits.com/dippin_stocks/message/650500248</stembedurl>Another user opined that the stock is going to be “highly volatile” but reach double digit.<stembedurl>https://www.stocktwits.com/momoneyinfla/message/650499935</stembedurl><a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has fallen by about 95% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM">ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments PR Newswire VANCOUVER, BC, Feb. 27...

New Strong Sell Stocks for Jan. 13

ATAI, BHR and BZH have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

<ul class="summary-bullets"><li>GH Research is scheduled to update on the FDA status of GH001 and outline its global Phase 3 plans for treatment-resistant depression on Monday.</li><li>The update follows the company’s submission of a complete response to the FDA after a prior clinical hold.</li><li>Progress across competing psychedelic-based depression programs has increased focus on the stock.</li></ul>Shares of GH Research PLC drew increased retail attention on Monday ahead of a scheduled update on its FDA Investigational New Drug application for GH001, the company’s inhaled therapy for treatment-resistant depression, and its plans for a global Phase 3 program, due at 7:00 a.m. EST.<h2 class="st-heading-2">Phase 3 Program And FDA Update In Focus</h2>The update follows the company’s June disclosure that it submitted a complete response to the FDA addressing a previously announced clinical hold on the IND. At the time, GH Research said the submission included completed toxicology studies and comprehensive responses to the agency’s requests, adding that it had worked closely with regulators and submitted the response ahead of schedule.<h2 class="st-heading-2">GH001 Data Anchors Development Path</h2>GH001 is GH Research’s lead experimental therapy, delivered through a proprietary inhalation system and designed to treat patients with treatment-resistant depression, a condition where standard antidepressants have failed.In February 2025, the company reported results from a Phase 2b study involving 81 patients. Those treated with GH001 showed a significant improvement in depression symptoms within eight days, with scores on a standard clinical scale falling by an average of 15.5 points more than placebo. The difference was statistically significant.Over half of the patients receiving GH001 achieved remission by Day 8, compared with none in the placebo group. The company said all secondary study goals were met, and the treatment was well tolerated, with no serious adverse events reported during the blinded phase of the trial.Longer-term follow-up data showed sustained benefits. Among patients who completed six months of follow-up, nearly 78% remained in remission, with most requiring only a small number of additional treatments. As of late January 2025, the company reported no serious safety issues during this extended period.<h2 class="st-heading-2">Psychedelic Race Intensifies</h2>In November, H.C. Wainwright lowered its price target on GH Research to $35 from $40 while maintaining a ‘Buy’ rating, citing competitive momentum from programs such as Atai Beckley’s BPL-003 and AbbVie’s GM-2505, as well as the prior FDA hold.In October, Needham initiated coverage with a ‘Buy’ rating and a $19 price target, citing GH001’s Phase 2 efficacy and remission data and estimating potential U.S. sales of $1.9 billion by 2035.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for GH Research was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:968/143;" src="https://news.stocktwits-cdn.com/ghrs_ss_png_215c6b80c9.webp" alt="ghrs ss.png" width="968" height="143"><figcaption>GHRS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user grouped GH Research alongside names like Disney, Marathon Digital, Critical Metals and Navitas Semiconductor, saying the stock continues to sit within a cluster of “hot themes” across the market.<stembedurl>https://stocktwits.com/JoyceFernandez/message/640797658</stembedurl>Another user said they plan to sell part of their position around the FDA update to lock in gains and hold the rest into the next company update later in the quarter.<stembedurl>https://stocktwits.com/NoobFriendly/message/640797043</stembedurl><a href="https://stocktwits.com/symbol/GHRS">GH Research’s stock</a> has risen 89% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the GH Research logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment

GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression.

<ul class="summary-bullets"><li>The analyst noted that sponsors must continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health.</li><li>Jefferies added that it believes Atai Beckley's (ATAI) proprietary psychedelics have promise.</li><li>The AdvisorShares Psychedelics ETF (PSIL), which invests in the emerging psychedelic drugs sector, traded 1.3% higher at the time of writing.</li></ul>Jefferies analyst Andrew Tsai now sees positive tailwinds forming for non-recreational psychedelics after President Trump signed an executive order on Thursday directing his administration to reclassify marijuana.The firm now sees non-recreational psychedelics eventually follow suit, as long as sponsors continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health. This, the analyst believes, is arguably a function of time.&nbsp;Jefferies added that it believes pharmaceutical company Atai Beckley's (<a href="https://stocktwits.com/symbol/ATAI">ATAI</a>) proprietary psychedelics have promise. AtaiBeckley’s pipeline includes investigational therapies for treatment-resistant depression and social anxiety disorder.Shares of psychedelics-related stocks rallied on Friday. While ATAI stock traded 0.4% higher at the time of writing, Supernus (<a href="https://stocktwits.com/symbol/SUPN">SUPN</a>) and Cybin (<a href="https://stocktwits.com/symbol/CYBN">CYBN</a>) shares rose about 5%.The AdvisorShares Psychedelics ETF (<a href="https://stocktwits.com/symbol/PSIL">PSIL</a>), which invests in the emerging psychedelic drugs sector, also traded 1.3% higher.<h2 class="st-heading-2">Trump Cannabis Order</h2>President Donald Trump on Thursday <a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-stock-rise-as-trump-signs-executive-order-to-lower-marijuana-restrictions/cLegUFuREr0">signed</a> an executive order to reschedule marijuana to make it less restrictive and available for “legitimate medical uses.” Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research. The Centers for Medicare &amp; Medicaid Services (CMS) is also working on a plan to test making some Medicare patients eligible for therapies derived from cannabinoids or compounds derived from the Cannabis plant.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PSIL fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while sentiment around ATAI also took a dip to ‘extremely bearish’ levels.Sentiment around SUPN stayed ‘neutral,’ while sentiment around CYBN stayed ‘extremely bullish’.A Stocktwits user highlighted a positive study from 2022 on Psilocybin, a naturally occurring psychedelic compound, in treating depression symptoms.<stembedurl>https://www.stocktwits.com/DJS777/message/639663641</stembedurl>As per the study published in the New England Journal of Medicine, participants reported a greater reduction in levels of depression three weeks after taking a 25 mg dose of psilocybin, compared to those who took the lowest 1 mg dose.PSIL has gained 68% this year and by 76% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-on-track-for-worst-day-in-about-9-months/cLe0RFtREsu">Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Digitally generated image of brain filled with multicolored particles. | Source: Getty Images

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order

Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.  

Enhanced Fortifies Executive Leadership Team & Board of Directors

Enhanced Fortifies Executive Leadership Team & Board of Directors Enhanced Fortifies Executive Leadership Team & Board of Directors PR Newswire NEW YORK, Nov. 19, 2025 Co-Founder Maximilian Martin...

atai Life Sciences (ATAI) Upgraded to Buy: Here's Why

atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

Psychedelic stocks are surging as traders price in an executive order accelerating research and FDA fast-track pathways for mental health treatments.

Momentum is flooding into mental health biotechs as traders hunt for the next explosive breakout within the high-beta psychedelic sector.

Increased interest in ibogaine research is driving institutional and retail attention toward companies leading the specialized addiction-treatment pipeline.

Analysts and investors are recalibrating price targets upward as positive research updates and institutional support strengthen long-term sentiment.

Current Price	$5.00
Prev Close	$4.03
Open	$5.03
Dividend Yield	0.00%
50-Day Moving Average	$3.74
Beta	1.51
Avg. Volume	5.38M
PE Ratio	-1.75

52-Week High	$6.75
52-Week Low	$1.29
Market Capitalization	$1.47B
EPS (Annual)	-$2.91
Price to Book	6.60
Revenue Per Employee	$34,948.72

ATAI
AtaiBeckley Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATAI News

ATAIAtaiBeckley Inc.